GSK2636771 – 500 µg

Brand:
Cayman
CAS:
1372540-25-4
Storage:
-20
UN-No:
Non-Hazardous - /

Phosphatidylinositol 3-kinase (PI3K) catalyzes the phosphorylation of phosphatidylinositol at the 3 position to produce the second messengers phosphatidylinositol-3,4-bisphosphate (PtdIns-(3,4)-P2 and PtdIns-(3,4,5)-P3). Class 1 PI3Ks are composed of a p110 catalytic subunit, of which there are four isoforms (p110α, p110β, p110δ, and p100γ), and a p85 regulatory subunit. GSK2636771 is an orally bioavailable inhibitor of PI3K p110β.{30758} At 1-10 µM, it decreases cell viability and Akt phosphorylation in p100β-dependent PTEN-deficient PC-3 prostate and BT549 and HCC70 breast cancer cell lines.{29910}  

 

Available on backorder

SKU: - Category:

Description

An orally bioavailable inhibitor of PI3K p110β that decreases cell viability and Akt phosphorylation in p100β-dependent PTEN-deficient PC-3 prostate and BT549 and HCC70 breast cancer cell lines


Formal name: 2-methyl-1-[[2-methyl-3-(trifluoromethyl)phenyl]methyl]-6-(4-morpholinyl)-1H-benzimidazole-4-carboxylic acid

Synonyms: 

Molecular weight: 433.4

CAS: 1372540-25-4

Purity: ≥98%

Formulation: A crystalline solid


Product Type|Biochemicals|Kinase Inhibitors|PI3K||Product Type|Biochemicals|Small Molecule Inhibitors|Kinases||Research Area|Cancer|Cell Signaling|PI3K/Akt/mTOR Signaling